Atea Pharmaceuticals Stock Valuation

AVIR -  USA Stock  

USD 24.74  0.37  1.47%

How much is Atea Pharmaceuticals worth today? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Atea Pharmaceuticals, is its stock price multiplied by the total number of shares outstanding, calculating Atea Pharmaceuticals' enterprise value requires a different approach. It uses Atea Pharmaceuticals' balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Atea Pharmaceuticals Free Cash Flow is relatively stable at the moment as compared to the past year. Atea Pharmaceuticals reported last year Free Cash Flow of 296.71 Million. As of 07/26/2021, Tangible Asset Value is likely to grow to about 931.8 M, while Enterprise Value is likely to drop slightly above 3 B.
Atea Pharmaceuticals shows a prevailing Real Value of $26.56 per share. The current price of the firm is $24.74. At this time, the firm appears to be undervalued. Our model approximates the value of Atea Pharmaceuticals from analyzing the firm fundamentals such as return on equity of (3.86) %, and Profit Margin of (22.51) % as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor buying undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.

Search Valuation 

 
Refresh
Atea Pharmaceuticals Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Atea Pharmaceuticals's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Undervalued
Today
24.74
26th of July 2021
Share
Atea Pharmaceuticals is not too volatile asset. Calculation of real value of Atea Pharmaceuticals is based on 3 months time horizon. Increasing Atea Pharmaceuticals time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Our valuation method for Atea Pharmaceuticals is useful when determining the fair value of the Atea Pharmaceuticals stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Atea Pharmaceuticals. Since Atea Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Atea Pharmaceuticals Stock. However, Atea Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
26.56
Real Value
32.38
Upside
Estimating the potential upside or downside of Atea Pharmaceuticals helps investors to forecast how Atea Pharmaceuticals stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Atea Pharmaceuticals more accurately as focusing exclusively on Atea Pharmaceuticals' fundamentals will not take into account other important factors:
Earnings
Estimates (3)
LowProjected EPSHigh
-0.480.861.58
Details
Hype
Prediction
LowEstimated ValueHigh
19.2625.0830.90
Details
4 Analysts
Consensus
LowTarget PriceHigh
31.0033.0035.00
Details
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. Some money managers use Atea Pharmaceuticals' intrinsic value based on its ongoing forecasts of Atea Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by look to relative valuation against Atea Pharmaceuticals' closest peers. When choosing a valuation method Atea Pharmaceuticals, make sure it is appropriate for the firm given its current financial situation and market classification. If more than one is valuation category is appropriate, we suggest using both methods to arrive at a better estimate.

Atea Pharmaceuticals Valuation Drivers Correlation

Many accounts on the financial statements of Atea Pharmaceuticals are highly interrelated and sometimes correlated. Consequently, when conducting Atea Pharmaceuticals's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Atea Pharmaceuticals
Click cells to compare fundamentals

Atea Pharmaceuticals Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Atea Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Atea Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Atea Pharmaceuticals competition to find correlations between indicators driving Atea Pharmaceuticals's intrinsic value. More Info.
Atea Pharmaceuticals is rated fourth in price to earning category among related companies. It is rated below average in price to book category among related companies . . As of 07/26/2021, Price to Book Value is likely to drop to 5.64

About Atea Pharmaceuticals Valuation

The equity valuation mechanism determines the current worth of Atea Pharmaceuticals on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Atea Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Atea Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Atea Pharmaceuticals's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Atea Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Atea Pharmaceuticals. We calculate exposure to Atea Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Atea Pharmaceuticals's related companies.
Last ReportedProjected for 2021
Gross Profit43.8 M43.5 M
Profit Margin(0.20) (0.22) 
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.

Atea Pharmaceuticals Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Atea Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio2.71
Enterprise Value To Ebitda87.36
Enterprise Value To Revenue21.61

Atea Pharmaceuticals Current Valuation Indicators

Valuation refers to the process of determining the present value of Atea Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Atea Pharmaceuticals we look at many different elements of the entity such as Atea Pharmaceuticals's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Please continue to Trending Equities. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.